Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Home  /  Forum  /  BioPharma  /  HEB Memispherx

Ontvang nu dagelijks onze kooptips!

word abonnee

BioPharma« Terug naar discussie overzicht

HEB Memispherx

61 Posts
Pagina: 1 2 3 4 »» | Laatste | Omlaag ↓
  1. [verwijderd] 11 mei 2009 21:01
    BRIEF-Hemispherx Biopharma announces public equity offerings

    May 11 (Reuters) - Hemispherx Biopharma, Inc : * Announces $18.3 million public equity offerings * Says offering priced at $1.10 per share

    ((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780)) ((For more news, please click here [HEB.A]))

    Sheff quote:

    Hemispherx Biopharma (HEB): Ampligen (Poly I: Poly C12U) NDA (three month PDUFA decision date delay was announced on 2/18/09 as additional data was submitted by HEB within three months of original decision date). Ampligen is an experimental treatment for chronic fatigue syndrome (which has no FDA-approved treatments) and the drug has an Orphan Drug Status with a PDUFA decision date of 5/25/09.

  8. [verwijderd] 18 mei 2009 23:53
    Pump en dump trade
    maar geniet ervan als je trader bent

    HEB inquiry

    Hemispherx Biopharma Comments On Market Activity

    PHILADELPHIA, May 15, 2009 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) stated that in view of the unusual market activity in the Company's stock, the NYSE Amex has contacted the Company and requested that the Company issue a public statement indicating as to whether there are any corporate developments which may explain the unusual activity. The Company stated that there have been no material events other than as disclosed in its recent press releases and its filings with the Securities and Exchange Commission that would explain the high volume market activity.

    finance.yahoo.com/news/Hemispherx-Bio...

  18. [verwijderd] 23 mei 2009 17:50
    Chronic Fatigue Syndrome Treatment: FDA's Ampligen Decision Imminent
    Friday May 22, 2009

    Will the millions of people with chronic fatigue syndrome (CFS or ME/CFS) finally have an FDA-approved drug treatment? We should know soon, as the long-awaited decision on Ampligen (poly I: poly C12U) is due on or around May 25.

    Ampligen has languished in the "experimental" stage for 30 years. Then, in October 2007, Hemispherex Biopharma Inc. put in a New Drug Application for Ampligen as the first ever FDA approved treatment for ME/CFS. In July 2008, the company responded to questions sent back by the FDA, and the application was officially accepted. The decision was originally due in late February, but the FDA at that time announced it needed 3 more months. Now, it's just a matter of time before we hear yea or nay.

    Ampligen is an immume-system modulator that works by jump-starting your body's natural anti-viral pathway and regulating levels of Rnase L (a substance in your cells that attacks viruses), which can be high in people with ME/CFS. Studies show it's more effective and has far fewer side effects than other drugs in its class. Ampligen has also been studied as a possible treatment for AIDS, avian flu, and certain types of cancer.

    This drug has been available to certain U.S. clinics for several years, and there's a lot of evidence (both clinical and experiential) showing that it works. Some doctors claim they've seen improvement in 80% of people with ME/CFS who take Ampligen, and significant improvement in about 50%. They say a lot of seriously disabled people have even been able to go back to work because of it.

    Side effects are reportedly mild and include flu-like symptoms, dizziness and confusion. (After living with ME/CFS, would you even recognize those as side effects?)

    Here's more info from the manufacturer: Ampligen.

    chronicfatigue.about.com/b/2009/05/22...
  19. [verwijderd] 24 mei 2009 09:43
    Misschien morgen positief nieuws?????????

    Als je de artikelen leest,kan het bijna niet meer mis,maar dat is al vaker gedacht.

    Stukje uit een artikel,je zou toch zeggen dat...................................nah,eerst maar eens zien.

    Vriendelijke groet.

    As reported in BioMedReports this past week, HEB is expecting to hear from the FDA this coming week as to whether Ampligen receives approval as a chronic fatigue syndrome treatment.

    With the "boats loads" of safety data available, Ampligen could quickly be developed for H1N1 flu strain, Piros said. He noted that Hemispherx already has been in discussions with the CDC about its product

    biomedreports.com/articles/most-popul...
61 Posts
Pagina: 1 2 3 4 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 874,67 -1,06%
EUR/USD 1,0620 -0,05%
FTSE 100 7.820,36 -1,82%
Germany40^ 17.760,40 -0,03%
Gold spot 2.383,06 +0,03%
NY-Nasdaq Composite 15.865,25 -0,12%

Stijgers

Avantium
+5,13%
FASTNED
+2,27%
Air Fr...
+2,00%
DSM FI...
+1,84%
CM.COM
+1,69%

Dalers

Arcelo...
-6,90%
Aperam
-6,68%
JUST E...
-4,85%
SBM Of...
-4,17%
RANDST...
-3,69%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!